Fig. 5: The identity of SE-driven LIMD1-AS1 in glioma.
From: Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression
A Genome browser image at Chip-seq profiles for H3K27ac, MED1, Pol II at LIMD1-AS1 locus in GBM cells and NHA cell lines. B, C ChIP-qPCR analysis of the H3K27ac enrichment in the LIMD1-AS1 promoter and constituent enhancer regions. IgG antibody was used as a negative control. D, E ChIP-qPCR analysis of the MED1 enrichment in the LIMD1-AS1 promoter and constituent enhancer regions. IgG antibody was used as a negative control. F, G Luciferase reporter assays measured Promoter and Enhancer (E4, E5) activity of LIMD1-AS1 in LN-18 and T98G glioma cells. *P < 0.05, **P < 0.01. H sgRNAs designed to target the LIMD1-AS1 super-enhancer critical region using the dCas9-KRAB. I, J Blockade of LIMD1-AS1 super-enhancer critical region by two individual sgRNAs significantly reduced the expression of LIMD1-AS1. *P < 0.05, **P < 0.01. K, L Blockade of LIMD1-AS1 super-enhancer critical region by two individual sgRNAs reduced the proliferation in LN-18 and T98G glioma cells. **P < 0.01.
